170 related articles for article (PubMed ID: 36612001)
1. Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer.
Alannan M; Trézéguet V; Amoêdo ND; Rossignol R; Mahfouf W; Rezvani HR; Dittrich-Domergue F; Moreau P; Lacomme S; Gontier E; Grosset CF; Badran B; Fayyad-Kazan H; Merched AJ
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612001
[TBL] [Abstract][Full Text] [Related]
2. Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis.
Alannan M; Fatrouni H; Trézéguet V; Dittrich-Domergue F; Moreau P; Siegfried G; Liet B; Khatib AM; Grosset CF; Badran B; Fayyad-Kazan H; Merched AJ
Cells; 2022 Dec; 12(1):. PubMed ID: 36611859
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin.
Lupo MG; Marchianò S; Adorni MP; Zimetti F; Ruscica M; Greco MF; Corsini A; Ferri N
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923431
[TBL] [Abstract][Full Text] [Related]
4. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.
Rosoff DB; Bell AS; Jung J; Wagner J; Mavromatis LA; Lohoff FW
J Am Coll Cardiol; 2022 Aug; 80(7):653-662. PubMed ID: 35953131
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
7. Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9).
Wang Y; Ye J; Li J; Chen C; Huang J; Liu P; Huang H
Cardiovasc Diabetol; 2016 Feb; 15():19. PubMed ID: 26833058
[TBL] [Abstract][Full Text] [Related]
8. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
Ference BA; Robinson JG; Brook RD; Catapano AL; Chapman MJ; Neff DR; Voros S; Giugliano RP; Davey Smith G; Fazio S; Sabatine MS
N Engl J Med; 2016 Dec; 375(22):2144-2153. PubMed ID: 27959767
[TBL] [Abstract][Full Text] [Related]
9. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
10. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
11. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
12. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Khera AV; Qamar A; Reilly MP; Dunbar RL; Rader DJ
Am J Cardiol; 2015 Jan; 115(2):178-82. PubMed ID: 25432415
[TBL] [Abstract][Full Text] [Related]
13. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
[TBL] [Abstract][Full Text] [Related]
14. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity.
Chen PW; Tseng SY; Chang HY; Lee CH; Chao TH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077166
[TBL] [Abstract][Full Text] [Related]
15. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture.
Mbikay M; Sirois F; Simoes S; Mayne J; Chrétien M
FEBS Open Bio; 2014; 4():755-62. PubMed ID: 25349780
[TBL] [Abstract][Full Text] [Related]
16. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells.
Lan H; Pang L; Smith MM; Levitan D; Ding W; Liu L; Shan L; Shah VV; Laverty M; Arreaza G; Zhang Q; Murgolo NJ; Hernandez M; Greene JR; Gustafson EL; Bayne ML; Davis HR; Hedrick JA
J Cell Physiol; 2010 Jul; 224(1):273-81. PubMed ID: 20333646
[TBL] [Abstract][Full Text] [Related]
17. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
[TBL] [Abstract][Full Text] [Related]
18. Pro-inflammation NF-κB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells.
He M; Zhang W; Dong Y; Wang L; Fang T; Tang W; Lv B; Chen G; Yang B; Huang P; Xia J
J Exp Clin Cancer Res; 2017 Jan; 36(1):15. PubMed ID: 28100270
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
Kosmas CE; DeJesus E; Morcelo R; Garcia F; Montan PD; Guzman E
Drugs Context; 2017; 6():212511. PubMed ID: 29209403
[TBL] [Abstract][Full Text] [Related]
20. Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes.
Rohrbach S; Li L; Novoyatleva T; Niemann B; Knapp F; Molenda N; Schulz R
Front Physiol; 2021; 12():593862. PubMed ID: 33643060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
